SELF-INFUSING
WITH CONFIDENCE
Infusion Resources & Training
Infusion resources to help your patients manage therapy
CSL Behring is committed to partnering with you, providing a variety of support services for you and your patients. Explore these links for more information.
Best practices
Optimizing your patients’ self-infusion process
- Store Hizentra properly: it should be stored at room temperature (up to 25°C [77°F]) protected from light. No refrigeration required.
- If your patient has skin sensitivities to tape/adhesive, consider alternative methods to secure the needles in place
- Ensure pump settings match infusion rate
- Tubing size/length must also match infusion rate
- Choose a needle gauge consistent with the volume being infused
- Choose a needle length that penetrates subcutaneous tissue but not muscle or intradermal tissues
- Ensure needle is affixed securely and fully inserted without potential for movement
- Ensure there are no drops of Ig on needle prior to insertion (dry prime)
Select infusion sites:
- With appropriate amount of subcutaneous tissue (abdomen, thigh, upper arm, or side of upper leg/hip)
- That support optimal patient tolerability and comfort (rotate sites with each infusion)
- That do not promote needle movement during infusion
Infusion sites should be at least 2 inches apart and at least 1 inch from a previous infusion site. Never infuse into areas where the skin is tender, bruised, red, or hard. Avoid infusing into scars or stretch marks.
Monitor patient tolerability and adjust, as needed*:
- Total volume infused per site
- Rate of infusion
- Infusion site location
- Needle length
*For the first infusion of Hizentra, do not exceed a volume of 20 mL/site or a flow rate of 20 mL/h/site. For subsequent infusions, the volume per site and flow rate may be increased to 50 mL/site and 50 mL/h/site, respectively.
Abbreviation: Ig, immunoglobulin.
References: 1. Radley E, Hendricks L, Barrett L, Murphy E, Sivamurthy K. Real-world experience of needle length use based on BMI for IgPro20 administration. Poster P104 presented at: Immunoglobulin National Society (IgNS); 2023 Oct 5-8; Denver, CO. 2. Freedom60 Infusion System [instructions for use]. Mahwah, NJ: KORU Medical Systems; 2023. F60_Domestic_IFU_337126 Rev D. 3. SCIg60 Infusion System [user manual]. El Dorado Hills, CA: EMED Technologies Corporation; 2015. AS-0010021_2.0. 4. FreedomEdge Syringe Infusion System [instructions for use]. Mahwah, NJ: KORU Medical Systems; 2022. 347201 Rev A.
IMPORTANT SAFETY INFORMATION
WARNING: Thrombosis may occur with immune globulin products, including Hizentra. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
For patients at risk of thrombosis, administer Hizentra at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin (Ig) or components of Hizentra (eg, polysorbate 80), as well as in patients with immunoglobulin A deficiency with antibodies against IgA and a history of hypersensitivity. Because Hizentra contains L-proline as stabilizer, use in patients with hyperprolinemia is contraindicated.
IgA-deficient patients with anti-IgA antibodies are at greater risk of severe hypersensitivity and anaphylactic reactions. Thrombosis may occur following treatment with Ig products, including Hizentra.
Monitor patients for aseptic meningitis syndrome (AMS), which may occur following treatment with Ig products, including Hizentra. In patients at risk of acute renal failure, monitor renal function, including blood urea nitrogen, serum creatinine and urine output. In addition, monitor patients for clinical signs of hemolysis or pulmonary adverse reactions (eg, transfusion-related acute lung injury [TRALI]).
Hizentra is derived from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.
The most common adverse reactions (observed in ≥5% of study subjects) were local infusion-site reactions, as well as headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, upper respiratory tract infection, rash, pruritus, vomiting, upper abdominal pain, migraine, arthralgia, pain, fall, and nasopharyngitis.
The passive transfer of antibodies can interfere with response to live virus vaccines and lead to misinterpretation of serologic test results.
Indications
Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is indicated for:
- Treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years and older.
- Maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.
- Limitation of Use: Maintenance therapy in CIDP has been systematically studied for 6 months and for a further 12 months in a follow-up study. Continued maintenance beyond these periods should be individualized based on patient response and need for continued therapy.
For subcutaneous infusion only.
Please see full Prescribing Information for Hizentra including boxed warning.
To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
Hizentra Connect℠ is a service mark of CSL Behring LLC.